Form 4: Neurocrine Biosciences Director Sells Shares
Insider Transaction (Form 4)
Leslie Norwalk V, a Director of Neurocrine Biosciences Inc, sold 1,250 shares of common stock on July 28, 2026 for $182.01 per share.
Summary
- Open-market sale: disposed of 1,250 Common Stock at $182.01 ($227,508) on July 28, 2026; holds 1,588 after (Direct).
- Option exercise/conversion: acquired 842 Common Stock at $139.43 ($117,400) on July 29, 2026; holds 2,430 after (Direct).
- Option exercise/conversion: disposed of 842 Non-Qualified Stock Option on July 29, 2026; holds 2,140 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $227,508 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Leslie Norwalk V — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-28 | Open-market sale | Common Stock | 1,250 | $182 | $227.5K | 1,588 |
| 2026-07-29 | Option exercise/conversion | Common Stock | 842 | $139 | $117.4K | 2,430 |
| 2026-07-29 | Option exercise/conversion | Non-Qualified Stock Option | 842 | — | — | 2,140 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-28 | Open-market sale (1,250 shares) |
| 2026-07-29 | Option exercise/conversion (842 shares) |
| 2026-07-29 | Option exercise/conversion (842 shares) |
Keywords
insider transaction, Form 4, NBIX, NEUROCRINE BIOSCIENCES INC, bearish, Leslie Norwalk V
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.